Screening for cervical neoplasia: A community-based trial comparing Pap staining, human papilloma virus testing, and the new bi-functional celldetect® stain
Version of Record online: 31 MAY 2011
Copyright © 2011 Wiley Periodicals, Inc.
Volume 40, Issue 12, pages 1054–1061, December 2012
How to Cite
Idelevich, P., Kristt, D., Schechter, E., Lew, S., Elkeles, A., Terkieltaub, D., Rivkin, I., Bruchim, I. and Fishman, A. (2012), Screening for cervical neoplasia: A community-based trial comparing Pap staining, human papilloma virus testing, and the new bi-functional celldetect® stain. Diagn. Cytopathol., 40: 1054–1061. doi: 10.1002/dc.21729
- Issue online: 17 NOV 2012
- Version of Record online: 31 MAY 2011
- Manuscript Accepted: 6 APR 2011
- Manuscript Received: 16 FEB 2011
- cervical neoplasia;
- CellDetect® stain;
- cervical screening
Although cytological screening for cervical neoplasia has lowered mortality rates, current screening methods are plagued by sub-optimal sensitivity and/or specificity. The purpose of this study was to compare the performance of the new CellDetect® staining technology as a potential screening tool. This initial, non-blinded study, utilized samples are taken at a community-based clinic. The diagnostic results using CellDetect® were compared with the performance of Pap staining and human papilloma virus (HPV) testing on the same material, as well as the follow-up biopsies. These data were statistically analyzed in terms of sensitivity, specificity, predictive value (N.P.V and P.P.V), and inter-observer agreement. Bi-functional CellDetect® staining revealed morphological details and tinctorial properties that permitted recognition of neoplasia even at low magnification. Performance-wise, CellDetect® demonstrated non-inferiority for all statistical parameters to both Pap and HPV tests. Importantly, superior sensitivity compared with Pap staining was observed, as well as higher specificity than HPV testing with near equivalent sensitivity. We conclude that CellDetect® is a promising approach to early detection of cervical cancer because of its bi-functional capabilities that afford high sensitivity and specificity. The data suggest that this new methodology warrants further and more extensive clinical evaluation. Diagn. Cytopathol. 2012. © 2011 Wiley Periodicals, Inc.